基于“阳化气、阴成形”理论探析膀胱癌的因机证治

Discussion on the etiology, pathogenesis and prevention strategy of bladder cancer based on the theory of “yang transforms into qi and yin constitutes form”

摘要

膀胱癌是泌尿系统最常见的恶性肿瘤之一。“阳化气”不及，导致“阴成形”过盛，日久而形成结节、肌瘤、肿块等疾病。阳化气不足为膀胱癌发病基础、阴成形太过为发病之标，肿瘤术后，阴阳俱损，伏邪未清。临床诊治主要包括：健脾益肾、温阳化气以固本；辨证祛邪、扶阳抑阴以防变；扶助正气、温阳解毒以防复。并结合临床验案对基于“阳化气、阴成形”理论探析膀胱癌的因机证治进行阐述。

Abstract

Bladder cancer is one of the most common malignant tumors in the urinary system. Insufficiency in “yang transforming into qi” leads to excessive “yin constituting form”, which gradually gives rise to diseases such as nodules, myomas and masses. Deficiency of yang transforming into qi serves as the root cause of bladder cancer, while excessive yin taking material form acts as its manifestation. Clinical diagnosis and treatment mainly include the following aspects: post-tumor surgery, both yin and yang are impaired with lingering pathogenic factors remaining; fortifying the spleen and tonifying the kidney, warming yang and transforming into qi to consolidate the root; eliminating pathogenic factors based on pattern differentiation, supporting yang and restraining yin to prevent deterioration; and reinforcing healthy qi, warming yang and resolving toxins to prevent recurrence. Combined with clinical proven cases, this paper elaborates on the etiology, pathogenesis, syndromes and treatment of bladder cancer based on the theories of “yang transforming into qi” and “yin constituting form”.

关键词

阳化气，阴成形 / 膀胱癌 / 治疗 / 策略

Key words

yang transforming into qi, yin constituting form / bladder cancer / treatment / strategy

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] ZHANG Y, RUMGAY H, LI M, et al. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040[J]. J Glob Health, 2023, 13: 04109.

[3] HAN BINGFENG, ZHENG RONGSHOU, ZENG HONGMEI, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.

[4] 白云金, 李金洪, 魏强, 等. 膀胱癌病因学研究进展[J]. 现代泌尿外科杂志, 2014, 19(10): 693-697.

[5] 卢文斌, 王尉, 聂海波, 等. 膀胱癌的诊疗研究进展[J]. 中国医药科学, 2022, 12(13): 62-65, 130.

[6] CHAMIE K, LITWIN M S, BASSETT J C, et al. Recurrence of high—risk bladder cancer: a population—based analysis[J]. Cancer, 2013, 119(17): 3219-3227.

[7] 郑睿, 米其武, 李宇清. 膀胱癌治疗的研究现状[J]. 世界最新医学信息文摘（连续型电子期刊）, 2018, 18(A5): 91-93.

[8] 张金英. 膀胱癌术后患者预后影响因素[J]. 中国老年学杂志, 2022, 42(4): 830-833.

[9] 白慧明, 曹宏文, 冯懿赓, 等. 龙荔汤治疗非肌层浸润性膀胱癌前瞻性临床观察[J]. 中国中西医结合杂志, 2022, 42(12): 1458-1462.

[10] 程婷婷, 石惠, 张小倩. 消癥肾气汤联合PDCA模式干预膀胱癌术后化疗患者临床观察[J]. 光明中医, 2023, 38(10): 1949-1952.

[11] 何秀萍, 邢益涛, 颜建, 等. 扶正祛瘀解毒方联合表柔比星灌注化疗对老年非肌层浸润性膀胱癌术后复发的影响[J]. 中国老年学杂志, 2023, 43(20): 4922-4925.

[12] TAMAI M, TATARANO S, OKAMURA S, et al. microRNA—99a—5p induces cellular senescence in gemcitabine—resistant bladder cancer by targeting SMARCD1[J]. Mol Oncol, 2022, 16(6): 1329-1346.

[13] 李红蓉, 魏聪, 贾振华, 等. 气络学说指导抗衰老研究[J]. 中国实验方剂学杂志, 2022, 28(1): 7-15.

[14] GORGOULIS V, ADAMAS P D, ALIMONTI A, et al. Cellular senescence: defining a path forward[J]. Cell, 2019, 179(4): 813-827.

[15] 郝云, 赵一敏. 三焦膀胱水液代谢职司异同及临床意义探究[J]. 中国中医基础医学杂志, 2019, 25(8): 1038-1039.

[16] 程海波, 吴勉华. 周仲瑛教授“癌毒”学术思想探析[J]. 中华中医药杂志, 2010, 25(6): 866-869.

[17] WITJES J A, BRUINS H M, CATHOMAS R, et al. European association of urology guidelines on muscle—invasive and metastatic bladder cancer: summary of the 2020 guidelines[J]. Eur Urol, 2021, 79(1): 82-104.

[18] 王润兮, 杨舒涵, 房立源, 等. 中医药“以平为期”调整肿瘤免疫微环境稳态[J]. 肿瘤防治研究, 2023, 50(11): 1114-1120.

[19] 石智尧, 孙祎濛, 孟祥聚, 等. 国医大师王晞星巧用对药角药治疗膀胱癌经验探析[J]. 现代中医临床, 2025, 32(2): 83-87.

[20] 冯保荣, 徐伟玲, 马纯政. 包积解毒方防治膀胱癌术后经验总结[J]. 光明中医, 2019, 34(10): 1503-1504.

[21] 李克刚, 尹学来, 刘冬, 等. 扶正补虚、祛邪消癥法防治膀胱癌[J]. 中医杂志, 2017, 58(20): 1790-1792.

[22] 李杰, 吴承玉, 骆文斌, 等. 阳虚体质与疾病的相关性研究[J]. 辽宁中医杂志, 2008, 35(8): 1161-1162.

[23] 刘媛媛, 刘轶凡, 田楚箫, 等. 国医大师吕仁和治疗膀胱癌术后化疗尿路刺激征验案[J]. 山东中医杂志, 2023, 42(4): 401-404.

[24] 韩亚茹, 殷东风. 膀胱癌患者中医证候要素临床研究[J]. 中医药临床杂志, 2018, 30(11): 2066-2069.

基金资助

中国中医科学院西苑医院提升中医药临床循证证据级别研究专项(XYZX0201-05)

中国中医科学院西苑医院提升中医药临床循证证据级别研究专项(XYZX0202-02)